NCT04213859

Brief Summary

This study will assess emotional processes and their relation to treatment outcomes during Virtual reality exposure therapy for Flight Phobia. The researchers hypothesize treatment outcomes will be associated with positive changes in emotional constructs

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 24, 2019

Completed
Same day until next milestone

Study Start

First participant enrolled

December 24, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 30, 2019

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2023

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

June 17, 2026

Completed
Last Updated

June 17, 2026

Status Verified

May 1, 2026

Enrollment Period

3.7 years

First QC Date

December 24, 2019

Results QC Date

April 28, 2026

Last Update Submit

May 20, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Changes in FAS (Flight Anxiety Situations Questionnaire) Scores

    The Flight Anxiety Situations Questionnaire (Van Grewen, Spinhoven, Van-Dyck, \& Dikstra, 1999) is a 32-item, 5-point Likert-scale (1= no anxiety to 5=overwhelming anxiety). The FAS evaluates flight-related anxiety in various situations. We used the total score of the FAS which ranges from 32 to 160 with higher values indicating more flight-related anxiety. Thus, higher values reflect worse outcomes, and lower values reflect better outcomes. The total score is obtained by summing all items.

    Two weeks prior to therapy and one week after last therapy session (therapy includes 4 weekly 1-hour sessions over the course of 4 weeks)

  • Changes in FAM (Flight Anxiety Modality Questionnaire) Scores

    The Flight Anxiety Modality (FAM) questionnaire (Van Grewen et al. 1999) assesses somatic and cognitive aspects of Flight Phobia. It includes 18 items that are rated using a 5-point scale (1=not at all, 5=very intensely). We used the total score of the FAM which ranges from 18 to 90, with higher values indicating more flight-related anxiety. Thus, higher values reflect worse outcomes, and lower values reflect better outcomes. The total score is obtained by summing all items.

    Two weeks prior to therapy and one week after last therapy session (therapy includes 4 weekly 1-hour sessions over the course of 4 weeks).

Study Arms (2)

Virtual Reality Exposure Therapy (VRET)

EXPERIMENTAL

1. st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders. 2. nd stage: During the week prior to treatment, participants will complete a brief measure of emotion-related variables every evening at a fixed time (08:00 pm). 3. rd stage: Participants will receive therapy for fear of flying using a Virtual Reality (VR) simulator. Therapy sessions will be held once a week during 4 weeks. Participants will complete a brief measure of emotion-related variables at a random time during the 12 hours before the therapy session at a random time during the 12 hours after the therapy session. This will occur for every therapy session. 4. th stage: After treatment, participants will complete measures of fear of flying and emotional variables.

Behavioral: VRET - Virtual Reality Exposure Therapy

control

NO INTERVENTION

1. st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders. 2. nd stage: During five weeks no therapy will be administered. Participants will fill questionnaires as follows: During the first week, participants will complete emotional measures every evening at a fixed time (08:00 pm) 3. rd stage: During each of the following 4 weeks, participants will complete two emotional measures during a 24 hour period. 4. th stage: Participants will complete measures of fear of flying and emotional variables.

Interventions

VRET will include 4 weekly 1-hour sessions over the course of 4 weeks. The treatment protocol is based on the Virtual Reality (VR) treatment manual guidelines (Rothbaum \& Hodges, 1997,1999) and includes psychoeducation, anxiety management training, cognitive restructuring and exposure. The first therapy session focuses on creating an individually-tailored conceptualization and treatment plan. Following this process, participant and therapist conduct a short introductory VR flight exposure simulation to familiarize the participant with the VRET apparatus. The VRET apparatus is an advanced, large-scale VR system that allows maximal immersion within the virtual environment. The second, third and fourth sessions include psychoeducation, relaxation training, cognitive restructuring and individually-tailored VR exposures (the therapist can manipulate the turbulence level and other flight-related variables to fit participants' fears and current progress).

Virtual Reality Exposure Therapy (VRET)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosis of Flight phobia based on a structured interview
  • possession of a smartphone with an active data plan

You may not qualify if:

  • cardiovascular disease
  • neurological disorders and history of epilepsy
  • psychosis
  • major depression
  • suicidal behavior
  • substance abuse.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sheba Medical Center

Ramat Gan, Israel, Israel

Location

MeSH Terms

Conditions

Aerophobia

Results Point of Contact

Title
Prof. Idan M. Aderka
Organization
University of Haifa

Study Officials

  • Asaf Caspi, MD

    Sheba Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Ph.D. Senior Lecturer

Study Record Dates

First Submitted

December 24, 2019

First Posted

December 30, 2019

Study Start

December 24, 2019

Primary Completion

September 1, 2023

Study Completion

September 1, 2023

Last Updated

June 17, 2026

Results First Posted

June 17, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations